Nano Science and Technology Institute

Venture Profile: Vitrimark, Inc.

Vitrimark, Inc. exploits the unique advantages provided by nanoscale cryoimaging of biofluids to identify ultrastructural biomarkers for utility and integration in the drug development process.

President: Dr. Arijit Bose
Location: Rhode Island, USA
Industry: Biotech & Pharma
Venture is: Seed Level

Vitrimark, Inc. exploits the unique advantages provided by nanoscale cryoimaging of biofluids to identify ultrastructural biomarkers for utility and integration in the drug development process.

Vitrimark’s premise (patent application filed September, 2005) is that morphological variations in components present in biological fluids precede or occur simultaneously with functional changes. Monitoring ultrastructural changes that are correlated to functional and phenotypic variations has the potential for early detection of disease, classification of disease sub-categories and characterization of drug efficacy and toxicity. Because these changes are physical, the identification process does not require any a priori knowledge of specific biological targets. Therefore, this method alleviates the reliance on biochemical assays which probe functional alterations in genes and proteins, need a priori knowledge of their function, and require extensive assay development and optimization.

Vitrimark's initial target is structural biomarkers for prostate cancer; it will then target prediabetes and diabetes. Vitrimark received its initial funding from the Slater Technology Fund, and was recently a finalist in the 2008 Rhode Island Business Plan Competition.

RSS feed of Nano World News

↑ Back to Nano World News™

© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map

Fatal error: Call to undefined function share_scripts() in /export/home/apache/httpd-nrc/docs/news/item.html on line 36